Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

医学 杜瓦卢马布 内科学 实体瘤疗效评价标准 不利影响 放射外科 免疫疗法 肿瘤科 进行性疾病 放射治疗 无容量 胰腺癌 外科 胃肠病学 癌症 化疗 泌尿科
作者
Changqing Xie,Austin G. Duffy,Gagandeep Singh Brar,Suzanne Fioravanti,Donna Mabry‐Hrones,Melissa Walker,Cecilia Monge Bonilla,Bradford J. Wood,Deborah E. Citrin,Elizabeth M. Gil Ramirez,Freddy E. Escorcia,Bernadette A. Redd,Jonathan Matthew Hernandez,Jeremy L. Davis,Billel Gasmi,David Erwin Kleiner,Seth M. Steinberg,Jennifer Clare Jones,Tim F. Greten
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:26 (10): 2318-2326 被引量:102
标识
DOI:10.1158/1078-0432.ccr-19-3624
摘要

PURPOSE: The effectiveness of immune checkpoint inhibitors (ICI) is limited in pancreatic ductal adenocarcinoma (PDAC). We conducted a phase I study to evaluate the safety of ICI with stereotactic body radiation therapy (SBRT) in patients with metastatic PDAC. PATIENTS AND METHODS: Patients enrolled must have received at least one line of prior systemic chemotherapy for metastatic disease. Cohorts A1 and A2 received durvalumab every 2 weeks plus either 8 Gy in one fraction of SBRT on day 1 or 25 Gy in five fractions on day -3 to +1. Cohorts B1 and B2 received durvalumab plus tremelimumab every 4 weeks and either 8 Gy in one fraction of SBRT on day 1 or 25 Gy in five fractions on day -3 to +1. ICIs were continued until unacceptable toxicity or disease progression. The primary objective was the safety and feasibility of treatment. Objective response was assessed in lesions not subjected to SBRT. RESULTS: Fifty-nine patients were enrolled and 39 were evaluable for efficacy. No dose-limiting toxicities were seen. The most common adverse event was lymphopenia. Two patients achieved a partial response (one confirmed and the other unconfirmed). The overall response rate was 5.1%. Median PFS and OS was 1.7 months [95% confidence intervals (CI), 0.8-2.0 months] and 3.3 months (95% CI, 1.2-6.6 months) in cohort A1; 2.5 months (95% CI, 0.1-3.7 months) and 9.0 months (95% CI, 0.5-18.4 months) in A2; 0.9 months (95% CI, 0.7-2.1 months) and 2.1 months (95% CI, 1.1-4.3 months) in B1; and 2.3 months (95% CI, 1.9-3.4 months) and 4.2 months (95% CI, 2.9-9.3 months) in B2. CONCLUSIONS: The combination of ICI and SBRT has an acceptable safety profile and demonstrates a modest treatment benefit in patients with metastatic PDAC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
珍珠发布了新的文献求助30
刚刚
柒九发布了新的文献求助10
刚刚
刚刚
领导范儿的应助被绯红逍遥采纳,获得10
1秒前
1秒前
kris发布了新的文献求助10
1秒前
QDU的应助被嘟嘟嘟采纳,获得20
1秒前
支摇伽发布了新的文献求助10
1秒前
复嘟嘟完成签到,获得积分10
2秒前
Nole的应助被观的采纳,获得30
2秒前
DW的应助被瑞达采纳,获得10
2秒前
搜集达人的应助被张顺采纳,获得10
2秒前
义气的哈密瓜完成签到,获得积分10
3秒前
搜集达人的应助被Hello_Alina采纳,获得10
3秒前
小黄发布了新的文献求助10
3秒前
Celeste完成签到 ,获得积分10
3秒前
kipo完成签到 ,获得积分10
3秒前
王十七发布了新的文献求助10
3秒前
4秒前
wanci的应助被爽朗的小王同学采纳,获得10
4秒前
瓶子完成签到 ,获得积分10
4秒前
甜美无剑发布了新的文献求助10
4秒前
李健的小迷弟的应助被youyyuy采纳,获得10
5秒前
6秒前
彳亍完成签到,获得积分10
6秒前
7秒前
斯文败类的应助被王新涛采纳,获得10
7秒前
7秒前
2339822272发布了新的文献求助10
7秒前
我是谁的应助被小胖采纳,获得30
8秒前
充电宝的应助被云晓采纳,获得10
9秒前
充电宝的应助被阿楠采纳,获得10
9秒前
yyt完成签到 ,获得积分10
9秒前
爆米花的应助被dan1029采纳,获得10
9秒前
Hello的应助被dan1029采纳,获得10
9秒前
李爱国的应助被dan1029采纳,获得10
9秒前
CodeCraft的应助被dan1029采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287